Document Detail


Somatostatin-receptor 2 (sst2)-mediated effects of endogenous somatostatin on exocrine and endocrine secretion of the rat stomach.
MedLine Citation:
PMID:  15655503     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Somatostatin is a potent inhibitor of gastric acid secretion. Its effects are mediated through five specific receptor subtypes (sst(1-5)), of which sst(2) is dominant on the enterochromaffin-like (ECL) cell and the parietal cell. To study the paracrine mechanisms of somatostatin, the sst(2)-specific antagonist PRL-2903 was used. Effects of PRL-2903 on acid secretion and release of histamine were studied in the totally isolated, vascularly perfused rat stomach. Further, the release of histamine and gastrin after bombesin, alone and in combination with PRL-2903, were studied. Results are presented as mean+/-standard error of the mean (s.e.m.). PRL-2903 concentration-dependently increased the venous histamine concentration from basal 55.6+/-7.5 to 367+/-114 nM at 50 microM PRL-2903. With 10 microM PRL-2903, venous histamine output increased from baseline 6.2+/-0.5 to 20.9+/-4.9 nmol h(-1); P=0.008. The combination of 520 pM gastrin and 10 microM PRL-2903 increased venous histamine output from 41.7+/-7.3 nmol h(-1) with gastrin alone to 95.2+/-9.8 nmol h(-1); P=0.016. Further, 10 microM PRL-2903 increased acid output from baseline 8.5+/-1.8 to 37.4+/-11 micromol h(-1); P=0.017. When combined with 10 microM ranitidine, PRL-2903 did not significantly stimulate acid secretion. Bombesin/PRL-2903 increased venous histamine concentration from 50.4+/-14.8 to 292+/-64.2 nM; P=0.008, and gastrin concentration from 38.6+/-13.1 to 95.8+/-20.3 pM; P=0.037. Endogenous somatostatin exerts a continuous restraint on histamine and gastrin release from the gastric mucosa and significantly reduces baseline acid secretion.
Authors:
Vidar Fykse; David H Coy; Helge Lyder Waldum; Arne Kristian Sandvik
Related Documents :
17148373 - Mosquito repellents in frog skin.
3092653 - Effect of a single oral dose of enprostil on gastric secretion and gastrin release. stu...
11566643 - Alpha-linolenic acid intake is not beneficially associated with 10-y risk of coronary a...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  144     ISSN:  0007-1188     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-02-07     Completed Date:  2005-06-13     Revised Date:  2013-06-09    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  416-21     Citation Subset:  IM    
Affiliation:
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NO-7489 Trondheim, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
1-Methyl-3-isobutylxanthine / pharmacology
Animals
Bombesin / pharmacology
Dose-Response Relationship, Drug
Endocrine Glands / drug effects*
Exocrine Glands / drug effects*
Gastric Acid / metabolism
Gastrins / metabolism,  pharmacology
Histamine / pharmacology
Histamine Release / drug effects
Hormone Antagonists / pharmacology*
Male
Peptides, Cyclic / pharmacology
Phosphodiesterase Inhibitors / pharmacology
Rats
Rats, Wistar
Receptors, Somatostatin / drug effects*
Somatostatin / pharmacology,  physiology*
Chemical
Reg. No./Substance:
0/Gastrins; 0/Hormone Antagonists; 0/PRL 2903; 0/Peptides, Cyclic; 0/Phosphodiesterase Inhibitors; 0/Receptors, Somatostatin; 0/somatostatin receptor 2; 28822-58-4/1-Methyl-3-isobutylxanthine; 31362-50-2/Bombesin; 51-45-6/Histamine; 51110-01-1/Somatostatin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconst...
Next Document:  The expanding field of cannabimimetic and related lipid mediators.